Sugi Predict

Sugi Predict / Compounds / SCHEMBL1702085

SCHEMBL1702085

SCHEMBL1702085

O=[C]CCCCCCCCCCCCCCCCCCC(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.63
▸ LMNA P02545 2/20 0.63
▸ NFKB1 P19838 1/20 0.63
▸ PMP22 Q01453 1/20 0.63
▸ HSD17B10 Q99714 2/20 0.62
▸ CYP1A2 P05177 1/20 0.62
▸ CYP2D6 P10635 1/20 0.62
▸ MAPT P10636 1/20 0.62
▸ CYP2C9 P11712 1/20 0.62
▸ CYP2C19 P33261 1/20 0.62
▸ PTPN7 P35236 3/20 0.56
▸ HMGCR P04035 3/20 0.56
▸ GPR84 Q9NQS5 4/20 0.52
▸ FFAR1 O14842 2/20 0.52
▸ FFAR4 Q5NUL3 2/20 0.52
▸ PPARG P37231 5/20 0.50
▸ PPARD Q03181 5/20 0.50
▸ PPARA Q07869 5/20 0.50
▸ HDAC11 Q96DB2 4/20 0.50
▸ ALDH1A1 P00352 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16701316 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL970516 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL7382880 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL6539108 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL3972155 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL3980051 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL374773 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL1654498 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL1401237 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10
SCHEMBL7292218 1.00 TSHR (0.63) TSHRLMNANFKB1PMP22HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024149820-A1 NMU RECEPTOR 2 AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-07-18 — — WO claimed
WO-2024133382-A1 GLP1/GIP/NPY2 RECEPTOR TRIPLE AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-06-27 — — WO claimed
EP-3551651-B1 ACYLATED GLP-1/GLP-2 DUAL AGONISTS ZEALAND PHARMA AS (DK) 2024-03-06 — — EP claimed
CN-117384274-A Acylated GLP-1/GLP-2 dual agonists 西兰制药公司 2024-01-12 — — CN claimed
US-20230405087-A9 ACYLATED GLP-1/GLP-2 DUAL AGONISTS ZEALAND PHARMA A/S (DK) 2023-12-21 — — US claimed
US-20230340039-A1 NPY2 RECEPTOR AGONISTS BOEHRINGER INGELHEIM INT (DE) 2023-10-26 — — US claimed
US-20230192770-A1 COMPSTATIN ANALOGUES AND THEIR MEDICAL USES ZEALAND PHARMA A/S (DK) 2023-06-22 — — US claimed
EP-4192853-A1 SOLUBLE NPY2 RECEPTOR AGONISTS Boehringer Ingelheim International GmbH (DE) 2023-06-14 — — EP claimed
CN-116171282-A Soluble NPY2 receptor agonists 勃林格殷格翰国际有限公司 2023-05-26 — — CN claimed
US-20230000951-A1 ACYLATED GLP-1/GLP-2 DUAL AGONISTS ZEALAND PHARMA AS (DK) 2023-01-05 — — US claimed
EP-3066117-A1 GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS Zealand Pharma A/S (DK) 2016-09-14 — — EP claimed
US-20160257729-A1 GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS ZEALAND PHARMA A/S (DK) 2016-09-08 — — US claimed
EP-3046573-A2 AMYLIN ANALOGUES Zealand Pharma A/S (DK) 2016-07-27 — — EP claimed
WO-2015067716-A1 GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS ZEALAND PHARMA A/S (DK) 2015-05-14 — — WO claimed
WO-2015067715-A2 GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS ZEALAND PHARMA A/S (DK) 2015-05-14 — — WO claimed
WO-2015040182-A2 AMYLIN ANALOGUES ZEALAND PHARMA A/S (DK) 2015-03-26 — — WO claimed
US-20120172298-A1 GLP-1 AND FGF21 COMBINATIONS FOR TREATMENT OF DIABETES TYPE 2 NOVO NORDISK A/S (DK) 2012-07-05 — — US claimed
EP-2440235-A1 GLP-1 AND FGF21 COMBINATIONS FOR TREATMENT OF DIABETES TYPE 2 Novo Nordisk A/S (DK) 2012-04-18 — — EP claimed
WO-2010142665-A1 GLP-1 AND FGF21 COMBINATIONS FOR TREATMENT OF DIABETES TYPE 2 NOVO NORDISK A/S (DK) 2010-12-16 — — WO claimed
US-6268343-B1 HUMAN GLUCAGON-LIKE PEPTIDE-1; MORE PROTRACTED PROFILE OF ACTION THAN THE PARENT PEPTIDES; TREATING DIABETES AND OBESITY; Liraglutide NOVO NORDISK A/S (DK) 2001-07-31 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230405087-A9 ACYLATED GLP-1/GLP-2 DUAL AGONISTS GLP1R, GIPR, GPR119 TSHR 313/4885LMNA 2721/4885NFKB1 4088/4885
US-20160257729-A1 GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS GLP1R, GIPR, GCGR TSHR 57/4885LMNA 4019/4885NFKB1 4234/4885
US-20230000951-A1 ACYLATED GLP-1/GLP-2 DUAL AGONISTS GLP1R, GIPR, GPR119 TSHR 313/4885LMNA 2721/4885NFKB1 4088/4885
US-20230340039-A1 NPY2 RECEPTOR AGONISTS NPY2R, NPY1R, NPY5R TSHR 259/4885LMNA 2884/4885NFKB1 3375/4885
US-20230192770-A1 COMPSTATIN ANALOGUES AND THEIR MEDICAL USES C1QBP, C9, VIP TSHR 1041/4885LMNA 1380/4885NFKB1 2017/4885
US-20120172298-A1 GLP-1 AND FGF21 COMBINATIONS FOR TREATMENT OF DIABETES TYPE 2 GLP1R, IAPP, FGF1 TSHR 2446/4885LMNA 807/4885NFKB1 2954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.